NEW PUBLICATION: Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder

NEW PUBLICATION: Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder

Category: Press Release

Press Release

Scioto Biosciences and Abigail Wexner Research Institute at Nationwide Children’s Hospital Receive a $2.3 Million Dollar Phase II SBIR Grant to Develop Novel Therapy

Press Release

Scioto Biosciences, Inc. Announces First Patient Dosed in Phase Ib Study in Patients Diagnosed with Autistic Disorder

Press Release

Scioto Biosciences Receives Series B Investment from Genome & Company

Press Release

Scioto Biosciences Presents Single-dose, Single Strain Pre-clinical C. diff Intervention at American Academy of Pediatrics National Conference & Exhibition

Press Release

Scioto Biosciences to Present at Microbiome Movement – Drug Development Summit in Boston